openPR Logo
Press release

Drug Discovery Services Market Expected to Behold a CAGR of 8.9% through 2017 to 2026

07-31-2018 02:39 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact. MR

Drug Discovery Services Market Expected to Behold a CAGR of 8.9%

Drug discovery services have undergone a drastic change with the advancements in modern molecular biology methods and advanced knowledge of human genome. Drug discovery is becoming more hypothesis-driven target-based approach. Pharmaceutical companies and regulatory bodies are contributing to the drug discovery. Major pharmaceutical companies are also focusing on developing the team of excellent scientists working in many therapeutic fields and technologies. In the recent years, there has been an increase in a number of approvals for first-in-class drugs, this reflects the impact of advanced drug discovery technologies, and approaches. Drug discovery service providers are also focusing on sequencing of the human genome in order to open the way to genomics-based methods in drug discovery. Innovation currently seen in the drug discovery methods is based on more information about targets, disease phenotypes, and compounds.

The report compiled by Fact.MR expects the global drug discovery services market is to witness robust growth, registering CAGR of 8.9% during 2017-2026. By the end of 2026, the global drug discovery services market is projected to reach US$ 16,800.1 million revenue. Increasing prevalence of chronic diseases and new diseases is driving the drug discovery services. Also, new technologies supporting drug discovery methods and techniques are evolving at a significant phase. Following are insight on how the global drug discovery services market will perform in the near future.

Request Report Sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=375

6 Key Insights on Global Drug Discovery Services Market

North America is likely to remain dominant in the global drug discovery services market throughout the forecast period 2017-2026. Presence of leading pharmaceutical companies in the region is one of the factors driving the growth of drug discovery services in North America.
Asia Pacific Excluding Japan (APEJ) is also anticipated to witness significant growth during 2017-2026. India and China are slowly becoming preferred locations for drug discovery outsourcing due to the technological capabilities developed. Fewer regulations and low manufacturing costs are also fueling the growth in APEJ region.
Hit-To-Lead identification is likely to be the most preferred process in the global drug discovery services market. By the end of 2026, hit-to-lead identification is projected to reach nearly US$ 7,000 million revenue.
By drug discovery service type, medicinal chemistry is likely to witness the significant growth. Towards the end of 2026, medicinal chemistry is projected to surpass US$ 6,000 million revenue.
Small molecules are anticipated to be the largest drug type in the global drug discovery service market. Small molecules are projected to create an incremental opportunity of more than US$ 5,800 million between 2017 and 2026.
On the basis of therapeutic area, highest growth is expected to be seen in oncology. Oncology is projected to reach nearly US$ 7,000 million revenue towards the end of 2026.

Request Report Methodology @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=375

The report offers a profile of some prominent players in the global drug discovery services market, which will stay active through 2026. The leading companies are Thermo Fisher Scientific, Inc., Merck Millipore, GE Healthcare, Albany Molecular Research, Inc. (AMRI), Charles River Laboratories International, Evotec, Pharmaceutical Product Development, LLC. (Ppd), Covance, Jubilant Biosys, Genscript Biotech Corporation, Aurigene Discovery Technologies, Wuxi Apptec, and Syngene.

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Drug Discovery Services Market Expected to Behold a CAGR of 8.9% through 2017 to 2026 here

News-ID: 1154913 • Views:

More Releases from Fact. MR

Mental Fitness Apps Market: A Leading Revenue Contributor, Forecasted to Grow at 16.7% CAGR till 2033
Mental Fitness Apps Market: A Leading Revenue Contributor, Forecasted to Grow at …
In 2023, the global market for mental fitness apps is valued at US$ 551.44 million and is anticipated to undergo rapid expansion, surging at a Compound Annual Growth Rate (CAGR) of 16.4% to reach US$ 2.52 billion by 2033. The escalating adoption of mental health applications is attributed to their transformative impact on lifestyle enhancement and treatment efficacy. Additionally, a growing societal awareness surrounding mental well-being is driving heightened demand for
Demand for the Point of Care Diagnostics Market is projected to reach a value of US$ 8,83,156.2 million by 2034
Demand for the Point of Care Diagnostics Market is projected to reach a value of …
In 2020, the Point of Care Diagnostics market size reached US$ 34.1 Billion, and it is expected to reach US$ 66 Billion by 2028. The Compound Annual Growth Rate (CAGR) during the forecast period from 2021 to 2028 is projected to be 7%. Market Dynamics: The Point of Care Diagnostics market is propelled by several key factors. First and foremost is the rising prevalence of infectious diseases and chronic conditions worldwide. The
Ceramic Coatings Market Value Is Expected To Increase At A CAGR Of Around 8.2% B …
The Ceramic Coatings market is estimated at US$ 7.4 Bn in 2022 and is projected to reach at a valuation of US$ 15.8 Bn by 2032, expanding at a CAGR of 8.2% during the forecasted period of 2022-2032. Ceramic coatings are made up of components like Silica, Silicon carbide, Alumina-magnesia, Alumina, Titania, and Silicon nitride. It is an inorganic substance which is made and well as applied at high temperatures. Ceramic
High Speed Ovens Market to Hit US$ 10.70 Billion By 2033
The global high speed ovens market is estimated at US$ 5.59 billion in 2023. Overall market value is expected to reach US$ 10.70 billion by 2033, expanding at a healthy CAGR of 6.7% from 2023 to 2033. High speed ovens are a type of cooking appliance that uses convection, microwave, and radiant heating technologies to cook food quickly. They are also referred to as accelerated cooking ovens or rapid cook ovens.

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug